EHA 2026: Nurix Therapeutics' CEO Arthur Sands discusses this week's big collaboration deal with Roche, and highlights the company's EHA data and broader platform
- 34 minutes ago
- 1 min read
He says he believes the Roche deal is an important transaction for the entire field of degraders. Plus, discussing antibody-degrader conjugates and an update on the company's immunology programs as well.






.png)
